HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
Source: onclive.com
Page 3 - Dose Reduction News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dose Reduction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dose Reduction Today - Breaking & Trending Today
First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL
Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.
Source: onclive.com
RR DTC: Managing Adverse Events With Dose Reductions or Holds
Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.
Source: onclive.com
Landscape of HER2+ Metastatic Breast Cancer: Patient Overview
Expert oncologist Kevin Kalinsky, MD, MS, reviews a patient case of HER2+ metastatic breast cancer and highlights key findings in this disease setting.
Source: onclive.com
Genetic Counseling for Patients with Non-Clear Cell RCC
The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
Source: onclive.com